Should You Buy Hikma Pharmaceuticals Plc, Circassia Pharmaceuticals PLC & Hutchison China MediTech Limited On Today’s News?

Can Hikma Pharmaceuticals Plc (LON:HIK), Circassia Pharmaceuticals PLC (LON:CIR) and Hutchison China MediTech Limited (LON:HCM) boost your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

How good is the investment case for Hikma Pharmaceuticals (LSE: HIK), Circassia Pharmaceuticals (LSE: CIR) and Hutchison China MediTech (LSE: HCM) after all three firms released news today?

Hikma Pharmaceuticals

Hikma Pharmaceuticals has grown so big since listing on the stock market in 2005 that it was promoted to the FTSE 100 earlier this year. Acquisitions have been part of Hikma’s growth strategy, but today it announced its biggest deal to date.

Hikma is to acquire Roxane Laboratories and Boehringer Ingelheim Roxane (together “Roxane”) from parent company Boehringer Ingelheim for a total consideration of $2.65bn: $1.18bn in cash and 40 million new Hikma shares at £23.50 a share.

Roxane is a US generics company, and the acquisition will catapult Hikma to the no. 6 position in the US generics market. Last year, Hikma made $763m revenue from the US and $633m from its other major territory, the Middle East and North Africa. Hikma expects Roxane to achieve revenue of $725m-$775m in 2017, and, assuming the acquisition completes in the last quarter of this year, the Board expects the deal to be accretive to adjusted earnings per share (EPS) in 2016 and “strongly accretive” to adjusted EPS from 2017 onwards.

Hikma’s shares are up over 6% in the wake of the news, but at just over £22 are below the £23.50 Boehringer Ingelheim sees as an acceptable valuation. I rate Hikma a buy at this level.

Circassia Pharmaceuticals

Circassia Pharmaceuticals is developing a pipeline of allergy treatments that are superior to traditional treatments by building up immunity quicker and without the risk of anaphylactic shocks. Circassia is in the FTSE SmallCap index, but raised £275m in June for two acquisitions and to fully fund its pipeline. As a result, the company’s market capitalisation has risen to well over £800m (at a current share price of a little under £3), putting it firmly in line for promotion to the FTSE 250 at the next quarterly review, in September.

On the face of it, this seems to be an over-elevated status for a company that is expected to be loss-making for some time to come. Circassia today reported a half-year loss widening to £22m from £16m in the same period last year, but said its “late-stage programs and phase III studies are on track” — and its share price is little changed on the day.

It’s difficult to put a valuation on Circassia, but renowned fund manager Neil Woodford was happy to participate in the June fundraising, which was at a level not much below the current share price.

Hutchison China MediTech

Hutchison China MediTech (“Chi-Med”), whose vision is to become a major China-based pharmaceutical company, reported a “strong outlook for full year and beyond” in its half-year results today. Nevertheless, the shares fell more than 7% to under £16 in early trading this morning — and well down from a high of close to £20 in May.

Chi-Med is one of the bigger companies on the AIM market, being valued at over £900m. In contrast to Circassia, the company is growing revenues fast, and is profitable. In its first-half results today, Chi-Med reported revenue on continuing operations up 117% to $65.7m. Net profit to equity holders fell to $2.3m from $5.6m, but I don’t see this as any cause for concern. Chi-Med is using cash from its profitable “Commercial Platform” of healthcare and consumer products to fund its exciting drug “Innovation Platform” — in particular, during the first half, “pushing our oncology and immunology clinical pipeline as hard and fast as we could”.

Chi-Med’s Commercial Platform already has 1,800 medical sales staff, covering about 13,500 hospitals and over 80,000 doctors — a ready-made network for commercialising the company’s own Innovation Platform drugs once approvals start to come through. With profits currently being recycled into clinical activity, valuing the company on earnings is not particularly helpful. Strong forecast revenue growth, though, and price-to-sales ratios, suggest the stock could be worth buying at the current level.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »